Skip to main content
Premium Trial:

Request an Annual Quote

Nuclera Acquires E Ink Digital Microfluidics Business

NEW YORK – Biotech company Nuclera said on Wednesday that it is acquiring the digital microfluidics business unit of electronic ink technology provider E Ink for an undisclosed amount.

Following the acquisition, the E Ink business unit will operate as the US subsidiary of Cambridge, UK-based Nuclera.

Nuclera, which develops enzymatic protein and gene synthesis technologies, said it will combine the companies' technologies to finalize the development of a desktop protein and gene bioprinter with applications for human health, agriculture, and other markets.

Since 2018, Nuclera and E Ink have been collaborating to deploy Nuclera's biopolymer synthesis technologies on E Ink's digital microfluidic devices, enabling users to digitally program bioprinting of proteins and genes on a desktop device. Nuclera expects to commercialize the bioprinter in 2022.

Under the terms of the deal, E Ink will contribute intellectual property, equipment, and scientists and engineers, and will become the largest strategic shareholder in Nuclera. The resulting Nuclera US subsidiary will be located within the E Ink Innovation Center in Billerica, Massachusetts. E Ink will also continue to supply Nuclera with key electronic components for the desktop bioprinter.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.